{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045964","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.719284+00:00","generated_at":"2026-05-30T03:31:56.530018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS","bullets":["Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.","Cash $81.9M at Sep 30, 2024; subsequent $58.1M warrant exercise proceeds extend runway into at least 2027.","First patient dosed in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa; topline data expected 2026.","R&D expenses $9.5M, up from $1.2M YoY due to AVTX-009 trial initiation and development costs.","Total revenues minimal at $249K; operating loss $12.9M for the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045964","json":"https://secwatch.observer/filing/0001628280-24-045964.json","markdown":"https://secwatch.observer/filing/0001628280-24-045964.md","text":"https://secwatch.observer/filing/0001628280-24-045964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024045964/0001628280-24-045964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024045964/avtx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:31:56.530018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}